Targeting T cell killing with complement component C3-anti CD3 fusion proteins.
Imutran Ltd (A Novartis Pharma AG Company), Cambridge, United Kingdom.
W
W
Fecke
M
M
Koukidou
T C
TC
Farries
R A
RA
Harrison
D000818:Animals; D017252:CD3 Complex / Q000276:immunology*; D019556:COS Cells; D002460:Cell Line; D003176:Complement C3 / Q000494:pharmacology*; D003602:Cytotoxicity, Immunologic; D006801:Humans; D007128:Immunoglobulin Fragments / Q000494:pharmacology*; D007143:Immunoglobulin Heavy Chains / Q000494:pharmacology; D007147:Immunoglobulin Light Chains / Q000494:pharmacology; D007135:Immunoglobulin Variable Region / Q000494:pharmacology; D019169:Jurkat Cells; D011993:Recombinant Fusion Proteins / Q000494:pharmacology; D013601:T-Lymphocytes / Q000276:immunology*; D014162:Transfection
D017252:CD3 Complex; D003176:Complement C3; D007128:Immunoglobulin Fragments; D007143:Immunoglobulin Heavy Chains; D007147:Immunoglobulin Light Chains; D007135:Immunoglobulin Variable Region; D011993:Recombinant Fusion Proteins